New influenza target
Nature Biotechnology
May 31, 2010
A novel target for killing the influenza A virus is presented in Nature Biotechnology this week. The discovery of this target ― a viral protein called nucleoprotein and of a drug that can inhibit it may lead to the development of therapies for influenza infection.
Because new strains of influenza A virus continue to emerge, some of which may be resistant to current drugs, it is necessary to continue to develop new antiviral therapeutics and strategies. By screening a large library of small molecules, Richard Y Kao and colleagues found that a small molecule called nucleozin can suppress influenza A viral replication in both cell lines and mice. Nucleozin targets the viral protein nucleoprotein. Since the influenza A genome encodes only 11 proteins, the finding that nucleoprotein is druggable may represent a significant addition to the targets available to drug developers. The scientists believe that similar screens may uncover further targets.
doi: 10.1038/nbt.1638
Research highlights
-
Aug 12
Ageing: Mutations in the ageing human heart identifiedNature Aging
-
Aug 12
Palaeontology: T. rex and relatives traded big eyes for bigger bitesCommunications Biology
-
Aug 10
Epidemiology: Estimating the risk of SARS-related coronaviruses from bats in Southeast AsiaNature Communications
-
Aug 5
Microbiology: Single switch makes Escherichia coli beneficial insect partnerNature Microbiology
-
Aug 5
Conservation: More than half of unassessable species may be at risk of extinctionCommunications Biology
-
Aug 4
Physiology: Restoring cellular functions in pigs after deathNature